Goldman Restores Buy Rating on 4D Molecular, Cites Upcoming Catalysts (NASDAQ:FDMT)

Bull and bear financial newspaper facts

Goldman Sachs reinstated its buy rating on 4D Molecular Therapeutics (NASDAQ:FDMT), citing future catalysts.

The investment bank said it sees shares trading higher on catalysts that include 24-week data for 4D-150 in wet AMD and diabetic macular edema in 2H, FDA

Source link

Leave a Reply

Your email address will not be published. Required fields are marked *